Onconetix Inc (ONCO)
$5
Performance
- $4.91$5.17$5.00
1.8%
Downside
Day's Volatility :5.03%
Upside
3.29%
- $2.82$21.40$5.00
43.68%
Downside
52 Weeks Volatility :86.84%
Upside
76.64%
Returns
| Period | Onconetix Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -16.67% | 0.0% |
6 Months | -19.46% | 0.0% |
1 Year | 1062.79% | 0.0% |
3 Years | -91.29% | -20.8% |
Highlights
Market Capitalization | 41.5M |
Book Value | - $64.14 |
Earnings Per Share (EPS) | -109.2 |
Wall Street Target Price | 9.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -300.33% |
Return On Assets TTM | -21.85% |
Return On Equity TTM | -1758.48% |
Revenue TTM | 1.5M |
Revenue Per Share TTM | 2.89 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -15.1M |
Diluted Eps TTM | -109.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 80.0%
Technicals Summary
Sell
Neutral
Buy
Onconetix Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Onconetix Inc | 2.8% | -19.46% | 1062.79% | -91.29% | -91.29% |
 Regeneron Pharmaceuticals, Inc. | -10.93% | 8.12% | 21.23% | 85.29% | 239.25% |
 Novo Nordisk A/s | -9.85% | -6.35% | 25.79% | 137.8% | 353.05% |
 Alnylam Pharmaceuticals, Inc. | 5.73% | 77.74% | 60.24% | 32.45% | 248.92% |
 Vertex Pharmaceuticals Incorporated | -2.51% | 15.43% | 27.28% | 155.56% | 169.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Onconetix Inc | NA | NA | NA | 0.0 | -17.58 | -0.22 | NA | -64.14 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.47 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Onconetix Inc | Sell | $41.5M | -91.29% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 239.25% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 353.05% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 248.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.8B | 169.62% | 32.84 | -4.74% |
Company Information
developed by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in variability. these regions of the virus were shown in thompson et al 2018 to direct the antigenic evolution of the influenza virus and therefore make ideal vaccine targets. the vaccine thus negates the need for (i) annual vaccination, providing potentially life-long protection against flu, and (ii) reformulation of the vaccine every few years.
Organization | Onconetix Inc |
Employees | 12 |
CEO | Dr. Ralph Schiess Ph.D. |
Industry | Miscellaneous |
Discover More
Mohr Company Nav Etf
$5.00
-1.96%
Cnsmr Discret Alphadex Etf First Trust
$5.00
-1.96%
Pimco Etf Trust Pimco Mortgage-backed Securities Active Exchange-traded Fund
$5.00
-1.96%
Fuel Tech Inc
$5.00
-1.96%
Ishares Morningstar Small Growth Index Fund
$5.00
-1.96%
Kentucky First Federal Bancorp
$5.00
-1.96%
Pasithea Therapeutics Corp
$5.00
-1.96%
Ishares Intl Div Growth Etf
$5.00
-1.96%
Allianzim Us Large Cap Buffer10 Sep Etf
$5.00
-1.96%